26 Oct ICAP CRIF study: The wholesale trade in medicines reached 14.5 billion euros in 2025. Bucharest accounted for two-thirds of that amount.
Press release
October 26, 2026
ICAP CRIF study: The wholesale trade in medicines reached 14.5 billion euros in 2025. Bucharest accounted for two-thirds of that amount.
In 2025, the wholesale market for medicines and pharmaceutical products in Romania reached a value of 14.5 billion euros, equivalent to 73.11 billion lei, marking a 9% increase compared to 2024. This is according to a sectoral analysis by ICAP CRIF Romania, a market leader in credit risk solutions and business information in Southeast Europe.
Bucharest alone accounted for 66% of this turnover, amounting to nearly 9.6 billion euros in 2025. Argeș County ranked second, contributing 11% of the total, a figure generated by a single company!
“We conducted an in-depth look at the wholesale trade of pharmaceutical products and medicines for human use in 2025, comparing it with the preceding two years, and we uncovered many interesting aspects. For instance, the number of large companies has decreased, albeit marginally, while the number of micro and medium-sized enterprises has grown, also marginally,” explains Theodoros Polydoros, Executive Director of ICAP CRIF Romania.
The study reveals that the number of companies involved in the pharmaceutical wholesale sector saw a slight decline in 2025 compared to previous years. Specifically, last year there were 1,804 companies registered under NACE code 4646 (wholesale trade in pharmaceutical products and medicines for human use), compared to 1,835 in 2024 and 1,863 in 2023.
More than half of these firms are registered in the Bucharest-Ilfov and Muntenia regions, accounting for 86% of the total revenue in the pharmaceutical wholesale sector, while the fewest are found in Oltenia. The highest concentration of companies is in Bucharest (781 companies), followed by Ilfov County (178 companies).
The study analyses exclusively the financial results as submitted to the Ministry of Finance; these show an increase in aggregate turnover, as well as a 30% rise in net profit (in RON), reaching the equivalent of 0.9 billion euros (consolidated figure).
The number of employees in the pharmaceutical wholesale sector also saw a slight increase of 2.4%, reaching over 21,000 staff members.
The largest firms in the sector in 2025 were Fildas Trading SRL, followed by Alliance Healthcare România and Farmexim SA.
“This study is particularly complex and is part of the standard portfolio of reports and analyses that ICAP CRIF specialists produce for clients interested in investing across various sectors of the Romanian economy,” adds Theodoros Polydoros, Executive Director of ICAP CRIF Romania.
ICAP CRIF supports companies in all fields, as well as banks and other regulated entities, with data, analytics, and compliance solutions that help them identify risks more effectively, improve onboarding processes, and meet evolving regulatory requirements with confidence.
ICAP CRIF is part of the CRIF group, the market leader in credit risk solutions and business intelligence in South-Eastern Europe, which provides integrated expertise in the markets of Greece, Romania, Bulgaria and Cyprus.
ICAP CRIF provides innovative solutions structured in five main areas: business intelligence and credit risk management, rating services, marketing and sales solutions, advanced data technologies and analytics, as well as consulting services. Through these, the company supports organizations in strategic decision-making, risk assessment and sustainable development.
Follow ICAP CRIF Romania on LinkedIn.
